Please login to the form below

Not currently logged in
Email:
Password:

Depomed

This page shows the latest Depomed news and features for those working in and with pharma, biotech and healthcare.

Horizon swoops on Raptor to add rare disease products

Horizon swoops on Raptor to add rare disease products

The deal is Horizon's second acquisition this year after losing out on an earlier $3bn bid to buy specialty drugmaker Depomed.

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Asset swaps and divestments were a strong feature during 2014 and J&J has followed suit with the divestment to Depomed of the US rights to its Nucynta franchise (tapentadol for

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    275. Depomed / PDL Pharma. Royalty and milestone monetisation. Licence agreements in the type 2 diabetes therapeutic area.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Ron Menezes joins Almirall’s Aqua Pharmaceuticals Ron Menezes joins Almirall’s Aqua Pharmaceuticals

    Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS. ... Prior to his role at Depomed, Menezes was at Allergan in senior roles including vice president sales and marketing,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics